ZYKADIA, also known by its generic name ceritinib, is a targeted therapy medication used in the treatment of non-small cell lung cancer (NSCLC). Specifically, it is designed for patients whose cancer cells have an abnormal version of the anaplastic lymphoma kinase (ALK) gene, which can promote tumor growth. As an ALK inhibitor, ZYKADIA works by blocking the activity of the ALK protein, thereby slowing down or stopping the growth of cancer cells. It is typically prescribed to patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor. ZYKADIA is taken orally in capsule form and has been approved for use by various health regulatory agencies, including the U.S. Food and Drug Administration (FDA). Like all medications, it can cause side effects, and its use should be closely monitored by a healthcare professional.